Thesis pillars
- Gaap Loss But Fcf Positive→Stable
- Accelerating Revenue Growth↓Deteriorating
- Perfect Earnings Beat Streak↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 4, 2026
OrthoPediatrics Corp. (KIDS) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $30.87, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0).
OrthoPediatrics designs, develops and markets orthopedic implants, instruments and specialized braces built specifically for children, selling to hospitals across the United States and more than 75 international markets through independent sales agencies, distributors and direct... Read more
Hold if already holding. Not a fresh buy at $30.87, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.6/10, moderate confidence.
Passes 7/9 gates (positive momentum, no SEC red flags, news boost analyst 0.70, news boost analyst cluster(4), earnings proximity 115d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.
About OrthoPediatrics Corp.
About OrthoPediatrics Corp.
OrthoPediatrics generated $236.3 million in revenue for fiscal 2025, up from $204.7 million in 2024 and $148.7 million in 2023, marketing 87 surgical implant and bracing systems across trauma and deformity correction, scoliosis, and sports medicine — the three largest categories of the pediatric orthopedic market. The company sells to hospitals in the United States and more than 75 international countries, targeting a segment it estimates represents a $6.2 billion global opportunity, including $2.8 billion domestically.
The company sells through a hybrid channel of direct sales representatives, more than 30 independent U.S. sales agencies and over 80 international stocking distributors; sales agencies alone generated 56% of global revenue in fiscal 2025, down slightly from 59% in 2024. Implants and surgical instrumentation are produced under a contract manufacturing model, while orthotic and prosthetic bracing products are manufactured in-house, including through the 2024-acquired Boston Brace International subsidiary, which has continued acquiring O&P clinics in states including Virginia, Maryland, Florida, Colorado, North Carolina and New York through 2025. OrthoPediatrics also licenses third-party technology, including an extended distribution agreement for FIREFLY Technology running through 2030 and a 7D Surgical FLASH Navigation license extended through 2028, supplementing organic product development with in-licensed surgical navigation tools.
Show full overview
OrthoPediatrics' products remain subject to Humanitarian Device Exemption requirements and Institutional Review Board oversight, a regulatory pathway built for devices treating small patient populations — a fitting description for a market where the Pediatric Orthopaedic Society of North America counted roughly 1,500 members in 2025 versus approximately 33,400 U.S. surgeons focused on adults. The 10-K also flags dependency on its distribution network: the company's independent sales agencies and distributors, rather than direct hires, generated the majority of revenue, and losing that network could impair its ability to reach hospitals.
See also: Healthcare · Medical Devices
From OrthoPediatrics Corp.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-11-02Recent Developments — OrthoPediatrics Corp.
Latest news
- NEWS Jim Cramer says investors should consider buying SpaceX for their kids - CNBC — CNBC positive
- NEWS Truist Adjusts Price Target on OrthoPediatrics to $22 From $20, Maintains Hold Rating - Moomoo — Moomoo neutral
- NEWS Truist Adjusts Price Target on OrthoPediatrics to $22 From $20, Maintains Hold Rating - moomoo.com — moomoo.com neutral
- NEWS We’re waiting too long to help kids in crisis — and leaving foster care as the only option - Youth Today — Youth Today neutral
- NEWS Truist Adjusts Price Target on OrthoPediatrics to $22 From $20, Maintains Hold Rating - Yahoo Finance — Yahoo Finance neutral
Generated 2026-11-02T11:53:16Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $30.87, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0). Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Analyst target $26.75 reached (−13.3%), stop $28.71 (−7.5%), A.R:R -0.9:1. Score 5.6/10, moderate confidence.
Analyst target $26.75 reached (−13.3% from $30.87); no take-profit level is published. Analyst target $26.75 reached (−13.3%), stop $28.71 (−7.5%), A.R:R -0.9:1. Stop-loss: $28.71.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0); Overbought (RSI 83).
OrthoPediatrics Corp. trades at a P/E of N/A (forward -40.9). TrendMatrix value score: 5.1/10. Verdict: Hold.
14 analysts cover KIDS with a consensus score of 4.1/5. Average price target: $31.
What does OrthoPediatrics Corp. do?OrthoPediatrics designs, develops and markets orthopedic implants, instruments and specialized braces built...
OrthoPediatrics designs, develops and markets orthopedic implants, instruments and specialized braces built specifically for children, selling to hospitals across the United States and more than 75 international markets through independent sales agencies, distributors and direct sales representatives. The company generated $236.3 million in revenue for fiscal 2025, up from $204.7 million in 2024, using contract manufacturers for implants and in-house production for its orthotic and prosthetic bracing lines.